B-MS' I-O double act approved in third tumor type

US pharma major Bristol-Myers Squibb (NYSE: BMY) has scored an approval in a third tumor type with the combination of its two immuno-oncology drugs, Opdivo (nivolumab) and Yervoy (ipilimumab).

The US Food and Drug Administration (FDA) has approved the combination for adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.

This is an accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.